3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Withdrawn
1
Recruiting
1
Sponsor Class
OTHER
3
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
51
Thoracic
36
Gynecologic
6
Other solid neoplasm
3
Tumor-Agnostic
2
Lymphoid
2
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Neoplasms
1
Neoplasm Metastasis
1
Interventions
pembrolizumab
62
Paclitaxel
51
Gemcitabine
50
Carboplatin
45
Docetaxel
43
Cisplatin
31
Pemetrexed
30
Nivolumab
28
Bevacizumab
28
atezolizumab
22
Fluorouracil
22
Cetuximab
21
Capecitabine
21
Irinotecan
20
Leucovorin
19
Afatinib
18
Erlotinib Hydrochloride
15
trametinib
14
Trastuzumab
13
Ipilimumab
13
130-nm albumin-bound paclitaxel
13
regorafenib
11
olaparib
11
Sorafenib
11
Oxaliplatin
11
Drug Therapy
11
eribulin
10
enzalutamide
10
Midazolam
10
Injections
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Vinorelbine
×
Tumor-Agnostic
×
Clear all
NCT05999994
2026-03-27
CAMPFIRE
Eli Lilly and Company
Phase 2
Recruiting
105 enrolled
NCT03811418
2019-11-26
ATTILA
iOMEDICO AG
Phase 3
Withdrawn